Cutler Group’s Arcadia Biosciences RKDA Stock Holding History

Cutler Group’s Portfolio RKDA Stock Details RKDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-793	Closed	-$7K	–	6251
2021 Q2	$7K	Buy	793 +130	+20%	+$14.2K	﹤0.01%	4212
2021 Q1	$9K	Buy	+663	New	+$81.3K	﹤0.01%	3899

Other funds holding RKDA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Cutler Group's RKDA Position: Q1 2022 in Review

Cutler Group sold out of Arcadia Biosciences (RKDA) in Q1 2022, closing a stake of 8 shares.

Cutler Group first reported a position in RKDA in Q3 2021 and held it in 2 quarters. The position peaked at $0 in Q4 2021. 25 funds tracked by Wall St. Rank hold RKDA as of Q1 2022.

Cutler Group reported no remaining Arcadia Biosciences position as of Q1 2022 after selling out during the quarter.
Cutler Group sold 8 Arcadia Biosciences shares in Q1 2022.
Cutler Group first reported a position in Arcadia Biosciences in Q3 2021 and held it in 2 quarters.
Cutler Group's Arcadia Biosciences position peaked at $0 in Q4 2021.
25 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q1 2022.

Based on Cutler Group's 13F filing for Q1 2022, filed 14 Apr 2022.